Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KALOS trial of budesonide + glycopyrronium + formoterol versus budesonide + formoterol or Symbicort in inadequately controlled asthma
NL-OMON51184Phase 3Withdrawn
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide, glycopyrronium and formoterol in asthma (4 arms), sponsored by AstraZeneca. Primary endpoint: Change from baseline in morning pre-dose trough FEV1 over 24 weeks. Planned start Dec 2020; status: withdrawn.
02
Drugs
budesonideglycopyrroniumformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON51184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51184.